
    
      This was a Phase 4, open-label, randomized, multicenter (in the European Union), controlled
      study to assess the effect on lipid profile of switching from a stable highly active
      antiretroviral therapy (HAART) regimen of Kivexa + Kaletra to Truvada + Kaletra in adult
      HIV-1 infected subjects with raised cholesterol.
    
  